Wanfu Biotech (300482.SZ) will distribute 4 yuan for every 10 shares in 2023. The stock registration date is June 4
Wanfu Biotech (300482.SZ) announced that the company will implement the 2023 annual equity distribution, for every 10 shares...
Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The bad news is that even after the stocks recovery in the las
Is Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Recent Stock Performance Tethered To Its Strong Fundamentals?
Most readers would already be aware that Guangzhou Wondfo BiotechLtd's (SZSE:300482) stock increased significantly by 20% over the past month. Given the company's impressive performance, we decided
Wanfu Biotech (300482.SZ): As of March 31, 2024, the number of shareholders of the company was 41,501
Gelonghui, May 8 | Wanfu Biotech (300482.SZ) said on the investor interactive platform that as of March 31, 2024, the number of shareholders of the company was 41,501.
Wanfu Biotech (300482.SZ): US subsidiary respiratory triad home self-test OTC products obtained US FDA EUA authorization
Gelonghui May 5 丨 Wanfu Biotech (300482.SZ) issued an announcement that Wanfu Biotech's US wholly-owned subsidiary Wondfo USA Co. , Ltd. (hereinafter referred to as the “US subsidiary”) recently received a notice from U.S. Food & Drug Administration (US Food and Drug Administration, hereinafter referred to as “FDA”) that Wanfu Biotech's US subsidiary's trifecta household test kit for the novel coronavirus, influenza A virus, and influenza B virus (OTC version) WellLife COVID-1
Is Guangzhou Wondfo BiotechLtd (SZSE:300482) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Wanfu Biotech (300482.SZ): US subsidiary respiratory triple test products obtained US FDA EUA authorization
Gelonghui, April 22丨Wanfu Biotech (300482.SZ) announced that Wondfo USA Co., a wholly-owned subsidiary of the company in the US , Ltd. (hereinafter referred to as the “US subsidiary”) recently received a notice from the U.S. Food & Drug Administration (US Food and Drug Administration, hereinafter referred to as “FDA”) that the US subsidiary obtained the WellLife COVID19/influenza A & B trifecta test kit for the novel coronavirus, influenza A virus, and influenza B
Wanfu Biotech (300482.SZ) reported 2023 annual results, net profit of 488 million yuan, a year-on-year decrease of 59.26%
According to the Zhitong Finance App, Wanfu Biotech (300482.SZ) released its 2023 annual report, with revenue of 2,765 billion yuan, a year-on-year decrease of 51.33%. Net profit attributable to shareholders of listed companies was 488 million yuan, a year-on-year decrease of 59.26%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $415 million, a year-on-year decrease of 62.46%. The basic income per share is 1.10 yuan. A cash dividend of 4 yuan (tax included) is distributed to all shareholders for every 10 shares, 0 bonus shares (tax included), and 0 shares are transferred to all shareholders for every 10 shares using the capital reserve fund. The company focuses on the body
Individual Investors Are Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Biggest Owners and Were Hit After Market Cap Dropped CN¥442m
Key Insights Significant control over Guangzhou Wondfo BiotechLtd by individual investors implies that the general public has more power to influence management and governance-related decisions The
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Earnings Have Declined Over Three Years, Contributing to Shareholders 56% Loss
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) shareholders should be happy to see the share price up 18% in the last month. But that doesn't change the fact that the returns over the last three ye
Wanfu Biotech (300482.SZ) has been re-certified as a national high-tech enterprise
Gelonghui, February 26 | Wanfu Biotech (300482.SZ) announced that the company recently received the “High-tech Enterprise Certificate” (certificate number: GR202344009245) jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. (Date of issue: December 28, 2023, valid for three years).
There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'd want to identify a growing return on capital employ
Potential Upside For Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) Not Without Risk
With a median price-to-earnings (or "P/E") ratio of close to 31x in China, you could be forgiven for feeling indifferent about Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) P/E ratio of 33.6x. Al
Wanfu Biotech (300482.SZ): 2023 net profit pre-reduced by 57%-60%
Gelonghui, January 12 | Wanfu Biotech (300482.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 475.6 million yuan to 51.1 million yuan, down 57%-60% from the same period last year; net profit profit after deducting non-recurring profit and loss was 392.6 million yuan to 428.1 million yuan, down 61% to 64% from the same period last year. Since 2023, the company has taken “quality and cost” as the foundation of the company's strategy, upgraded “international integration” to a company-level business strategy, and moved from “large-scale growth” to “qualitative growth”
Guangzhou Wondfo BiotechLtd (SZSE:300482) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe
Wanfu Biotech (300482.SZ) plans to invest 50 million yuan in the Sanmei Phase II Fund to lay out the biological and health industry
Wanfu Biotech (300482.SZ) announced that the company, as a limited partner, plans to cooperate with Guangzhou Sanmei Investment Management Center (with...
Wanfu Biotech (300482.SZ) plans to acquire 30% of Songshan Lake Industrial's shares for 123 million yuan to promote the strategic layout of instruments
Wanfu Biotech (300482.SZ) announced that the company plans to invest in Guangzhou Wanxin Industrial Development Co., Ltd., a wholly-owned subsidiary...
Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Guangzhou Wondfo BiotechLtd (SZSE:300482) has had a great run on the share market with its stock up by a significant 26% over the last three months. As most would know, fundamentals are what usually
Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) 4.8% Gain Last Week Benefited Both Retail Investors Who Own 44% as Well as Insiders
Key Insights The considerable ownership by retail investors in Guangzhou Wondfo BiotechLtd indicates that they collectively have a greater say in management and business strategy A total of 8 invest
Wanfu Biology (300482.SZ): The company has no vaccine products
Gelonghui November 20 | Wanfu Biotech (300482.SZ) stated on the investor interactive platform that the company has no vaccine products yet. The company's business is concentrated in the field of in vitro diagnosis under the medical device sector, specializing in R&D, manufacturing, marketing and service of rapid diagnostic reagents and supporting instruments.
No Data